Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.60 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.60 |
| ▸ | CDC25A | P30304 | 4/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20210940 | 0.87 | CDC25A (0.50) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL19297675 | 0.83 | BRD4 (0.43) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL1377323 | 0.80 | CHRM2 (0.40) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL20218241 | 0.79 | ALDH1A1 (0.43) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL14560536 | 0.78 | RXFP1 (0.57) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL562794 | 0.77 | ALDH1A1 (0.60) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL281625 | 0.75 | ALDH1A1 (1.00) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL8791013 | 0.75 | ALDH1A1 (0.48) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL11802972 | 0.75 | MEN1 (0.54) | ALDH1A1ALDH2ALDH3A1CDC25ACES1 | |
| SCHEMBL8301869 | 0.74 | CHRM2 (0.48) | ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-1888592-B1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-04-06 | — | — | EP | disclosed |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| US-7799798-B2 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| WO-2008046065-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008046082-A2 | USE OF HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888592-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| US-20060252758-A1 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110654-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | ALDH1A1 807/4885ALDH2 444/4885ALDH3A1 1110/4885 |
| US-20060252758-A1 | Spiroheterocyclic compounds and their uses as therapeutic agents | SCN3A, SCN1B, SCN2B | ALDH1A1 1435/4885ALDH2 1835/4885ALDH3A1 506/4885 |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | ALDH1A1 807/4885ALDH2 444/4885ALDH3A1 1110/4885 |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | ALDH1A1 1200/4885ALDH2 1601/4885ALDH3A1 375/4885 |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | ALDH1A1 1200/4885ALDH2 1601/4885ALDH3A1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.